144 related articles for article (PubMed ID: 28849031)
1. Sanggenon C protects against pressure overload‑induced cardiac hypertrophy via the calcineurin/NFAT2 pathway.
Xiao L; Gu Y; Gao L; Shangguan J; Chen Y; Zhang Y; Li L
Mol Med Rep; 2017 Oct; 16(4):5338-5346. PubMed ID: 28849031
[TBL] [Abstract][Full Text] [Related]
2. Cisapride protects against cardiac hypertrophy via inhibiting the up-regulation of calcineurin and NFATc-3.
Zhou X; Zhang Q; Zhao T; Bai X; Yuan W; Wu Y; Liu D; Li S; Ju J; Chege Gitau S; Chu W; Xu C; Lu Y
Eur J Pharmacol; 2014 Jul; 735():202-10. PubMed ID: 24769415
[TBL] [Abstract][Full Text] [Related]
3. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
4. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
5. Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7.
Li X; Chu G; Zhu F; Zheng Z; Wang X; Zhang G; Wang F
Exp Cell Res; 2020 Jan; 386(1):111716. PubMed ID: 31734152
[TBL] [Abstract][Full Text] [Related]
6. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
Dai H; Jia G; Liu X; Liu Z; Wang H
Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
[TBL] [Abstract][Full Text] [Related]
7. Ginseng reverses established cardiomyocyte hypertrophy and postmyocardial infarction-induced hypertrophy and heart failure.
Moey M; Gan XT; Huang CX; Rajapurohitam V; Martínez-Abundis E; Lui EM; Karmazyn M
Circ Heart Fail; 2012 Jul; 5(4):504-14. PubMed ID: 22576957
[TBL] [Abstract][Full Text] [Related]
8. Testin protects against cardiac hypertrophy by targeting a calcineurin-dependent signalling pathway.
Gao L; Liu Y; Guo S; Xiao L; Liang C; Wang X
J Cell Mol Med; 2019 Jan; 23(1):328-339. PubMed ID: 30467953
[TBL] [Abstract][Full Text] [Related]
9. Betulinic Acid Protects DOX-Triggered Cardiomyocyte Hypertrophy Response through the GATA-4/Calcineurin/NFAT Pathway.
Yoon JJ; Son CO; Kim HY; Han BH; Lee YJ; Lee HS; Kang DG
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374365
[TBL] [Abstract][Full Text] [Related]
10. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
11. Shensongyangxin protects against pressure overload‑induced cardiac hypertrophy.
Shen DF; Wu QQ; Ni J; Deng W; Wei C; Jia ZH; Zhou H; Zhou MQ; Bian ZY; Tang QZ
Mol Med Rep; 2016 Jan; 13(1):980-8. PubMed ID: 26648261
[TBL] [Abstract][Full Text] [Related]
12. Puerarin attenuates pressure overload-induced cardiac hypertrophy.
Yuan Y; Zong J; Zhou H; Bian ZY; Deng W; Dai J; Gan HW; Yang Z; Li H; Tang QZ
J Cardiol; 2014 Jan; 63(1):73-81. PubMed ID: 23906530
[TBL] [Abstract][Full Text] [Related]
13. STING is an essential regulator of heart inflammation and fibrosis in mice with pathological cardiac hypertrophy via endoplasmic reticulum (ER) stress.
Zhang Y; Chen W; Wang Y
Biomed Pharmacother; 2020 May; 125():110022. PubMed ID: 32106379
[TBL] [Abstract][Full Text] [Related]
14. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling.
Shen DF; Tang QZ; Yan L; Zhang Y; Zhu LH; Wang L; Liu C; Bian ZY; Li H
Br J Pharmacol; 2010 Feb; 159(4):970-81. PubMed ID: 20105174
[TBL] [Abstract][Full Text] [Related]
15. Sanggenon C protects against cardiomyocyte hypoxia injury by increasing autophagy.
Gu Y; Gao L; Chen Y; Xu Z; Yu K; Zhang D; Zhang G; Zhang X
Mol Med Rep; 2017 Dec; 16(6):8130-8136. PubMed ID: 28983604
[TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway.
Lu M; Wang H; Wang J; Zhang J; Yang J; Liang L; Maslov LN
Planta Med; 2014 Jan; 80(1):63-9. PubMed ID: 24338553
[TBL] [Abstract][Full Text] [Related]
17. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 Inhibitor Attenuates the Development of Pathophysiological Cardiac Fibrosis in Mouse Hypertrophy via Suppression of the Calcineurin-NFAT and c-Raf-Erk Pathways.
Marunouchi T; Nakashima M; Ebitani S; Umezu S; Karasawa K; Yano E; Tanonaka K
J Cardiovasc Pharmacol; 2021 Jun; 77(6):822-829. PubMed ID: 34016843
[TBL] [Abstract][Full Text] [Related]
19. Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
Lu CC; Xu YQ; Wu JC; Hang PZ; Wang Y; Wang C; Wu JW; Qi JC; Zhang Y; Du ZM
Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):747-55. PubMed ID: 23624753
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
